CanSinoBIO Reports 43.8% Revenue Growth as Overseas Business and mRNA Pipeline Expand
核心洞察
CanSino Biologics reported approximately RMB550 million in revenue for the first half of 2026, up 43.8% year-on-year, with net loss attributable to shareholders narrowing significantly.
Overseas revenue reached RMB150 million, driven by expansion of mature products and new partnership models involving technology collaboration and local industrialization.
The company's Tripecia (搜索) three-component DTP vaccine received NDA approval in April 2026, while its 24-valent pneumococcal conjugate vaccine entered Phase I/II trials in May 2026.
CanSino Biologics Inc. ("CanSinoBIO," 06185.HK/688185.SH) reported revenue of approximately RMB550 million for the first half of 2026, an increase of 43.8% year-on-year, while its net loss attributable to shareholders narrowed significantly. The results, released on August 27, 2026, highlight the growing contribution of the company's international business, which generated overseas revenue of RMB150 million during the reporting period, even as demand in China's vaccine market remains challenging.
Overseas Growth Accelerates Amid Domestic Demand Pressure
In the first half of 2026, China's vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible, with "volume contraction and price decline" emerging as a widespread challenge across the industry.
This pressure appears to be industry-wide based on disclosed financial results. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year-on-year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year-on-year, despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year-on-year.
Against this backdrop, CanSinoBIO's international business growth is particularly noteworthy. The company's overseas revenue of RMB150 million was driven both by the continued expansion of mature products into overseas markets and by the further deepening of its international partnership models. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East.
Menhycia, CanSinoBIO's quadrivalent meningococcal conjugate vaccine, has obtained registration approvals in Indonesia and Argentina, with product supply already commenced in Indonesia. The company noted that its overseas business is evolving from a strategic initiative into an increasingly important contributor to performance, shifting from "exporting products" to "exporting capabilities and systems."
Portfolio Upgrades Strengthen the Commercial Foundation
Domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia, China's first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population.
iPneucia (搜索), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia has continued to expand market access and is now available in nearly 30 provincial-level markets across China.
Multi-Layered Pipeline Advances Toward Future Growth
CanSinoBIO is building a more sustainable and well-sequenced product pipeline through continued ramp-up of marketed products, advancement of products under regulatory review, and development of next-generation candidates.
Tripecia (搜索) (DT3cP Infant), the company's three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products, and the product has begun entering the market supply stage.
The Td5cp (搜索) vaccine for adolescents and adults, which has been granted Priority Review status, is expected to extend CanSinoBIO's pertussis vaccine portfolio to a broader population. Its New Drug Application has been accepted by China's National Medical Products Administration (NMPA). Additionally, the company's independently developed Adsorbed Tetanus Vaccine, Tetcia (搜索), has been formally approved, further strengthening the adult vaccine portfolio.
In pneumococcal vaccines, CanSinoBIO's 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, with participant enrollment across different cohorts progressing as planned. The company also continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats.
mRNA Platform and Therapeutic Applications
Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The company is conducting early-stage research into mRNA applications for glioblastoma (搜索), rhabdomyosarcoma (搜索) and cervical cancer (搜索), while also exploring in vivo CAR therapies. These programs remain at an early stage, with the company continuing to assess the potential of mRNA and related technologies in disease treatment.
On August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI (搜索) on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines.
The company's core platforms, including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, and formulation and delivery technologies, provide a foundation for continued product iteration and technology translation.
Innovation Supports Long-Term Development
CanSinoBIO's story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. The overseas business model has expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth.
These pathways point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. As more innovative products enter the market, more mature products expand overseas, and the company's technical capabilities extend further into international value chains, CanSinoBIO's growth runway is expanding from a single domestic market to the global market.